Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

Published: 07 September 2020

  • Views:

    Views Icon 655
  • Likes:

    Heart Icon 3


Full programme


This educational symposium first broadcast at the ESC Congress 2020 discusses how SGLT2 inhibitors should be utilised by cardiologists in everyday practice

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

Series overview

Part 1

Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

Part 2

SGLT2i are Cardiovascular Drugs

Part 3

Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?

Part 4

Case Discussion

Part 5

A Follow-up Discussion to the ESC 2020 Session

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

University of Manitoba, Canada

Dr Shelley Zieroth is at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

Dr Zieroth attended medical school at the University of Manitoba, where she went on to train in internal medicine and cardiology. She completed her postdoctoral clinical fellowship, specializing in advanced heart failure and cardiac transplant, at Toronto General Hospital. Dr Zieroth has lectured internationally on the subject of heart failure.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile